Think Mylan's done with M&A after its Pfizer deal? Think again

mylan
Mylan expects to close its Upjohn merger in mid-2020. (Mylan on YouTube)

Mylan is focused on closing its merger with Pfizer's Upjohn next year. But after that deal closes, the pumped-up company should have the firepower for more M&A to beef up its business further, an exec said. 

Asked about a "fragmented" generics market on a Tuesday conference call, Mylan CFO Ken Parks said he sees an opportunity to build on the combined company’s commercial presence and strike more deals after the merger. 

Set to debut in 2020, the new company will outline its own strategies, Parks said, but he believes the opportunity for M&A is there. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The statements came as Mylan reported third-quarter revenues of $2.96 billion, a 3% increase versus the same period last year. The company’s adjusted earnings per share for the quarter fell 6% to $1.17. Mylan and Upjohn are set to close their deal in mid-2020.

While Mylan suffered from increased competition and an ongoing Morgantown restructuring that cost $58 million in the third quarter, new launches so far generated $800 million in 2019. Overall for the year, Mylan expects $1 billion in revenues from its newly rolled-out products.  

RELATED: Here's how Pfizer's reorg and Mylan's identity crisis yielded a giant generics merger 

As execs push to close the big merger, Mylan has also been cleaning out its own pantry. The generics maker discontinued 350 products that made no “business rationale” to sell, Mylan President Rajiv Malik said on Tuesday’s call. While the moves will result in lower revenues, the discontinuations won't affect profits, he said.

Going forward, the portfolio review will be an “ongoing” process, Malik said, but Mylan doesn’t expect a “bolus” like the previous batch that it recently discontinued.  

Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.